Volume 2, Number 1 (March 2016)                   mazu-cmm 2016, 2(1): 24-29 | Back to browse issues page



DOI: 10.18869/acadpub.cmm.2.1.24

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Badiee P, Badali H, Diba K, Ghadimi Moghadam A, Hosseininasab A, Jafarian H, et al . Susceptibility pattern of Candida albicans isolated from Iranian patients to antifungal agents. mazu-cmm. 2016; 2 (1) :24-29
URL: http://cmm.mazums.ac.ir/article-1-86-en.html

Abstract:   (1766 Views)

Background and Purpose: Candidiasis is a major fungal infection, and Candida albicans is the major cause of infections
in humans. The Clinical and Laboratory Standards Institute (CLSI) developed new breakpoints for antifungal agents
against C. albicans. In this multi-center study, we aimed to determine the drug susceptibility profile of C. albicans,
isolated from Iranian population according to new species-specific CLSI.
Materials and Methods: Clinical samples were cultured on Sabouraud dextrose agar and were incubated at room temperature for seven days. The isolates were transferred to Professor Alborzi Clinical Microbiology Research Center, Shiraz,
Iran. C. albicans were identified by using API 20C AUX system. Broth microdilution method was used to determine
the minimum inhibitory concentrations (MICs) of amphotericin B, caspofungin, voriconazole, fluconazole, posaconazole,
itraconazole, and ketoconazole, based on CLSI document M27-S4 and new breakpoints for some azoles and caspofungin.
Results: Overall, 397 C. albicans were isolated from patients admitted to ten university hospitals in Iran. The MIC90
of the isolates to amphotericin B, caspofungin, voriconazole, fluconazole, posaconazole, itraconazole, and ketoconazole
were 0.125, 0.125, 0.125, 1, 0.064, 0.5, and 0.125 μg/ml, and rates of resistance were 0.5%, 0.3%, 3.8%, 2.8%, and 2.5%
for amphotericin B, caspofungin, voriconazole, fluconazole, and itraconazole, respectively.
Conclusion: According to our data, fluconazole is the drug of choice for management of patients at risk for systemic
candidiasis throughout the region, since it is cost-effective with low side effects.

Full-Text [PDF 387 kb]   (684 Downloads)    
Type of Study: Original Articles | Subject: Medical Mycology
Received: 2016/04/9 | Accepted: 2016/06/5 | Published: 2016/06/11

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Current Medical Mycology